New York, May 25, 2026, 18:03 (EDT)
- U.S. markets didn’t trade Monday because of Memorial Day. Nasdaq is set to reopen Tuesday.
- Repligen ended Friday at $115.06, gaining 1.5% for the session. Shares rose 11.9% over the past five days.
- CEO Olivier Loeillot is next set to present at William Blair’s growth conference on June 3.
Repligen shares rallied over the last five sessions heading into the Memorial Day break, but the stock is still deep in the red for the year. Now investors are trying to figure out if last week’s move signals a shift or was just a quick bounce. Nasdaq had Monday, May 25, as a market holiday. Normal trading is 9:30 a.m. to 4 p.m. ET.
Repligen (Waltham, Massachusetts) finished Friday at $115.06, a gain of 1.49% for the session and up 11.85% over five days. Shares are still down 29.78% for 2026. U.S. markets reopen Tuesday, so that’s where the stock stands for now.
What’s new: Repligen rolls into a slower, holiday-shortened week with CEO Olivier Loeillot set to give a company update. According to the company, Loeillot will talk at the William Blair 46th Annual Growth Stock Conference in Chicago on June 3 at 10:40 a.m. CT. A webcast will stream on Repligen’s investor-relations site.
Repligen’s stock got some support earlier this month after the first-quarter report. The company said Q1 revenue was $194 million, up 15% as reported and 11% on an organic basis — stripping out acquisitions, divestitures and currency swings. Repligen kept its outlook for full-year organic revenue growth at 9% to 13%.
Loeillot called it “a very strong start to the year”, citing “recent order trends” as backing for the full-year view, the company said. He said Repligen is sticking to “disciplined, intentional investment” and narrowing its focus after starting a Transformation Office and offloading the non-core Polymem filtration unit. Repligen Corporation
Repligen’s adjusted EPS came in at $0.48, up from $0.39 last year. The company now sees full-year adjusted EPS in the range of $1.97 to $2.05. Reported revenue guidance was set between $803 million and $833 million.
Repligen’s main business hasn’t changed. The company sells filtration, chromatography, process analytics and protein tools for making biological drugs. Its buyers are big biopharma firms and CDMOs—contract manufacturers that handle drug production or development for others.
The stock’s weekly move was bigger than gains in larger peers. Thermo Fisher Scientific dropped 0.3% Friday and Danaher was down 0.8%, according to the latest U.S. trading data.
Large-cap growth stocks had a decent session before the break, with the Invesco QQQ Trust up 0.4% Friday. The SPDR S&P 500 ETF added about 0.4% as well, showing solid risk appetite.
But the rally isn’t without risks. Repligen flagged in its quarterly filing that estimates have become tougher thanks to global conflicts, supply-chain trouble, forex swings and cost pressure on its customers. The company warned actual results may turn out different. The same document showed its disclosure controls and procedures were not effective at quarter-end due to earlier reported weaknesses in internal financial reporting controls. Management still said the financial statements were fairly stated in all material respects.
Bulls will be watching this week to see if last week’s gain holds up as trading resumes after the holiday. The bigger read comes next week at the William Blair event, where investors want to hear anything new on orders, margins, or where bioprocessing demand is headed.
